Keynote and Featured Speakers:
The Limits of Immunotherapy
Alan J. Korman, PhD, Senior Vice President, Human Immunology, Vir Biotechnology
Engineering More Effective, Safer CAR T Cell Therapies
Eric L. Smith, MD, PhD, Director of Translational Research, Immune Effector Cell Therapies, Dana-Farber Cancer Institute
Clinical Biomarkers of Response to Ciltacabtagene Autoleucel in Patients with Relapse or Refractory Multiple Myeloma
Katherine Li, Director, Clinical Sciences, Oncology Translational Research, Johnson & Johnson Innovative Medicine
In vivo and ex vivo Use of LNP-Mediated Technology to Treat Hematological Disorders
Stefano B. Rivella, PhD, Professor, Pediatrics, Children's Hospital of Philadelphia
In vivo Engineering of Immune Cells: Update from Umoja Biopharma
David J. Fontana, PhD, Chief Business and Strategy Officer, Umoja BioPharma